Introduction
The transfer of genes that control cell cycle progression and cell death constitutes a potential strategy for cancer treatment mediated by a cytostatic effect or the induction of apoptosis. In such therapeutic situations in which the antitumor effect is based on transgene toxicity, regulatory gene delivery systems are required that permit precise control over the level and kinetics of protein expression.
Over the past several years, different regulatory systems have been developed to approach the problem of target gene regulation.
1,2 Disadvantages of these systems in which transgene activity is regulated at the transcriptional level include basal activity in the absence of induction and low inducibility. As an improved strategy for the regulation of proteins on a post-translational level, fusion to the hormone-binding domain of the transcriptionally inactive mutant of the murine estrogen receptor has been proven valuable in rendering protein activity hormone-dependent. [3] [4] [5] The modified receptor is unable to bind estrogen yet retains normal affinity for the synthetic ligand 4-hydroxy-tamoxifen (4-OHT). Following administration of ligand the ER fusion proteins are rapidly activated by allowing translocation from the cytosol to the nucleus. 6 The effects and pharmacology of nonsteroidal antiestrogens, such as tamoxifen and its deriva- apoptosis in several human cancers. AdER-E2F1 expressed high levels of transgene over at least 1 week. Upon activation of E2F1 by the ligand 4-hydroxy-tamoxifen (4-OHT) the ER-E2F1 fusion protein correctly translocated from the cytosol to the nucleus, transactivated E2F-dependent promoters, and rapidly induced substantial E2F1-related toxicity. Finally, experiments in nude mice showed tightly regulated tumor growth suppression in vivo. Taken together, our system represents a powerful approach for tight regulation and rapid induction of cytotoxicity as the major criteria for safe gene delivery. Gene Therapy (2000) 7, 1317-1325.
tives, have been well characterized in animal and human trials, confirming their suitability for gene therapeutic approaches in humans. 7 For efficient delivery of potentially toxic targets, such as tumor suppressor genes or apoptosis genes, into cancer cells, adenovirus (Ad) vectors have become the vector of choice. Ad vectors are probably the most efficient vehicles currently available for delivering foreign genes into mammalian cells both in vitro and in vivo. 8 Numerous studies have shown that a wide variety of cell types and tissues of many different species can be transduced by adenovirus at high efficiencies, resulting in high levels of transgene expression. Further, Ad vectors normally do not integrate into the host genome, so target gene expression is transient. For gene therapeutic approaches using toxic transgenes, this is of advantage since expression is not required after tumor cell killing.
We developed an inducible Ad vector system, in which regulation of toxic gene products following gene delivery is achieved by fusion of the transgene to the 4-OHT regulable ER domain. To demonstrate the potential of our Ad vector-based inducible system as a gene therapy tool for regulated activation of cytotoxic targets, we used the pro-apoptotic E2F1 gene under control of a strong heterologous promoter of the murine cytomegalovirus (MCMV) immediate-early (IE) gene. Previous reports have indicated that although E2F1 activates genes required for Sphase, it also functions as a tumor suppressor by triggering massive apoptosis in several cellular systems under deregulated conditions. [9] [10] [11] For E2F1 function, the endogenous wild-type status of p53, p16 or RB, which may be a limitation for the use of p53 as an anti-cancer agent, is not a determinant, thus E2F1 has a wider spectrum of therapeutic activity than p53. 12 By using the hormone-inducible ER-E2F1 expressing Ad vector system, we show that the activity of the introduced chimeric protein is tightly regulated in vitro and in mice in vivo, making it a powerful approach for construction and safe therapeutic application of Ad vectors expressing toxic proteins.
Results
Construction of a regulable adenovirus vector We 13 and others [9] [10] [11] 14 have demonstrated previously that adenovirus vectors can efficiently deliver cytotoxic genes into tumor cells, resulting in tumor growth suppression and apoptosis. However, for safety reasons the use of potentially toxic genes requires control over transgene activity. Using the Ad vector-mediated gene transfer strategy, we constructed a recombinant E2F1 virus, where transgene-mediated toxicity is controlled by fusion to the tamoxifen-inducible estrogen receptor (ER) ligandbinding domain ( Figure 1 ). We inserted the regulable expression cassette, HAER-E2F1, in the adenoviral E1 region under control of the short MCMV IE promoter, previously shown to drive much higher levels of transgene expression than the HCMV promoter, 15, 16 terminated by the polyadenylation signal of simian virus 40 (SV40pA). The vectors AdEGFP and Ad-Luc, expressing the enhanced green fluorescence protein and luciferase, respectively, were generated as controls. Adenoviruses expressing foreign genes were obtained by homologous recombination using the pBHG10 system in 293 cells. 17, 18 To test the hormone-dependent activation of the E2F1 transcription factor in the AdER-E2F1 vector, we have chosen the human Saos-2 cell line which has been used in the majority of studies on E2F1-induced apoptosis. Following infection of AdER-E2F1 at a multiplicity of infection (MOI) of 50, the ER-E2F1 fusion protein was clearly detected after 24 h and elevated protein levels were expressed over at least 1 week in the absence of 4-OHT compared with Mock infected cells (Figure 2a) . A decline in ER-E2F1 protein expression on day 3 after infection in the presence of 4-OHT (data not shown) is most likely attributable to the ligand-induced apoptotic potential of E2F1. Very low levels of endogenous E2F1 were seen in uninfected Saos-2 cells, which were not always within the limits of detection. The relative expression levels in absorbance units (AU) analyzed by densitometer are shown in Figure 2b . The level of ER-E2F1 in vector infected Saos-2 cells was estimated to be 30-35-fold higher than endogenous E2F1 levels in these cells.
Tamoxifen-induced translocation of the adenoviral ER-E2F1 fusion protein
Previous data suggested that the activity of ER-fusion proteins is regulated by the ligand-induced translocation of the protein from the cytosol to the nucleus 6 as a consequence of OHT binding to the ER domain, the displacement of ER-associated cellular polypeptides and the unmasking of the E2F1 nuclear localization signal, located in the N-terminus of E2F1. 19 The subcellular localization of ER-E2F1 overexpressed by an Ad vector following infection was tested by immunofluorescence analysis. Saos-2 cells were infected with AdER-E2F1 at MOI 5 and stained for HA-tagged ER-E2F1 expression by using an anti-HA monoclonal antibody ( Figure 3 ). As shown in Figure 3a , in the absence of 4-OHT the gene product is located in the cytoplasm, while after addition of 4-OHT ligand, the majority of Ad vector expressed fusion protein is detected in the nucleus (Figure 3b ).
Figure 3 Subcellular localization of adenovirus-expressed ER-E2F1 fusion protein. Immunofluorescence of Saos-2 cells infected with AdER-E2F1 in the absence (a) or presence (b) of 4-OHT. Cells were stained by using an anti-E2F1 monoclonal antibody (KH95).

Inducible activation of E2F-site containing promoters
The tamoxifen-dependent functional activity of ER-E2F1 fusion protein in adenovirus-infected cells was analyzed by luciferase expression assays and RT-PCR. A luciferase reporter construct containing either a synthetic E2F promoter with six E2F DNA binding sites, pGL3TATA basic 6xE2F (Figure 4a ), or the human p14ARF promotor construct, E1␤-Luc (Figure 4b ), was transfected along with a ␤-gal standard into Saos-2 cells 24 h before the ER-E2F adenoviral infection. Following infection with a low MOI of 10, ER-E2F1 expression leads to a four-fold (6xE2F promoter) to 10-fold (p14ARF promoter) activation of E2F-regulated promoters, when 4-OHT was added to Ad vector infected cells, while no transactivation was observed in cells infected with the control vector ( Figure  4a ). However, in the presence of 4-OHT, the activity of the 6xE2F promoter in ER-E2F virus infected cells was significantly higher (two-fold) than in cells infected with the control virus AdE2F1 carrying E2F1 under control of the HCMV IE promoter, which could be attributable to the higher transcriptional activity of the MCMV IE promoter in several human tumor cell lines. 15, 16 With regard to this, it should be mentioned that although an Ad vector expressing E2F1 under the HCMV IE promoter could be easily rescued, we were unable to generate an E2F virus which is directly regulated by the MCMV IE promoter. As shown in Figure 4a , we did not observe a higher basal promoter activity of the reporter plasmid in the absence of 4-OHT in AdER-E2F1-infected cells than Gene Therapy
Figure 4 Tamoxifen-dependent target gene activation by ER-E2F1 protein following adenovirus infection. The activity of E2F-regulated promoters was analyzed by luciferase assay (a, b) and RT-PCR (c). For luciferase assay, Saos-2 cells were transiently transfected either with the (a) 6xE2F reporter (pGL3TATA basic 6xE2F) or the (b) p14ARF promoter construct, E1␤-Luc. Twenty-four hours later, cells were infected with AdER-E2F1 or AdEGFP in the absence (−) or presence (+) of 4-OHT, or AdE2F1, respectively. The luciferase activity is shown as relative luciferase units (RLU). The data shown are averages of triplicates after normalizing with ␤-gal standard. Standard deviation is indicated by error bars. (c) Endogenous cyclin E mRNA levels in response to ER-E2F1 induction by RT-PCR. RT-PCR was performed on total RNA samples of AdER-E2F1-infected serum-starved cells induced for 8 h by addition of 4-OHT compared with the 4-OHT free sample. Cyclin E expression in cells infected with Ad-Luc or induced by serum are shown as controls.
in cells that were transfected with the reporter plasmid alone, indicating that the adenovirus-delivered transgene is completely inactive in the absence of ligand.
We also tested the 4-OHT-inducible activity of the AdER-E2F1 fusion protein on endogenous cyclin E gene expression, as an important downstream-target of E2F in serum-starved Saos-2 cells by RT-PCR (Figure 4c) . Again, only in the presence of 4-OHT, viral infected cells showed a substantial increase in the cyclin E mRNA level at 8 h after induction. Since cyclin E is a cell cycle regulated gene, a less pronounced effect on cyclin E mRNA was also detectable in uninfected cells in the presence of serum. Based on these data, we conclude that the transcriptional activity of adenoviral transferred ER-E2F1 protein is tightly regulated by 4-OHT. Figure 4a ). Taken together, we were able to control the biological activity of the ER-E2F1 fusion protein after adenoviral transfer by modifying the dose of 4-OHT.
Considering the toxic potential of proapoptotic gene products, it is important to achieve transgene regulation at a desired time. Therefore, the kinetics of the regulatory system were analyzed by measuring luciferase gene expression in Saos-2 cells transfected with the pGL3TATA basic 6xE2F reporter followed by AdER-E2F1 infection. In infected cells, mRNA levels were analyzed after administration of 4-OHT and at different time intervals after 4-OHT withdrawal by semi-quantitative RT-PCR. As shown in Figure 5b , a significant increase in luciferase mRNA was detectable as early as 4 h after induction by 4-OHT. Importantly, RNA levels decreased shortly after tamoxifen withdrawal and reached basal expression levels at 2 to 4 h later, demonstrating that by infecting cells with our regulable Ad vector system E2F1 transgene activity can be both rapidly induced and turned off.
4-OHT-dependent induction of cytotoxicity through adenoviral ER-E2F1
Recent studies indicated that ectopic expression of E2F1 via an adenoviral vector suppresses in vitro and in vivo growth of several human tumor cell lines and quiescent fibroblasts by induction of apoptosis. To assess whether E2F1-induced cytotoxicity can be regulated in response to 4-OHT, primary fibroblasts and multiple human cancer cell lines were infected with AdER-E2F1 at a multiplicity of infection, which allows 100% transduction, as determined by flow cytometry analysis using a EGFP expressing Ad vector. As shown in Figure 6a , all tested cell lines, independent of the endogenous p53 or RB status, exhibited a profound loss of cell viability upon AdER-E2F1 infection after addition of ligand in serumcontaining medium compared with the growth rate of ER-E2F1 virus-infected cells in the absence of 4-OHT. Morphological changes were observed in all cell lines, with cells rounding up at day 2, as shown for H1299 cells (Figure 6b Figure  6c , II), followed by a significant increase of sub-G1 cells on day 3 (Figure 6c, IV) , indicative of apoptosis. In the absence of tamoxifen, no significant increase in the sub-G1 population was observed. Thus, Ad vector expressed ER-E2F1 is capable of inducing cytotoxicity due to apoptosis only in the presence of 4-OHT.
Inducible tumor growth suppression in nude mice
In view of the strictly 4-OHT-dependent apoptotic activity of the adenoviral ER-E2F1 fusion protein in all of the cell lines tested in vitro, we examined the effect of E2F1 regulation on the tumorigenicity of cells in vivo. Because of the lack of tumorigenicity of Saos-2 cells in nude mice, we used H1299 cells for tumor induction. We
Figure 6 Inducible transgene toxicity in AdER-E2F1 infected human fibroblasts and tumor cell lines. (a) Effect of adenoviral expressed ER-E2F1 fusion protein on cell viability of VH6 fibroblasts, H1299, Saos-2 and A549 tumor cells in the absence (solid bars) or presence of 4-OHT (hatched bars) measured by MTT assay 1 week after infection. Cell viability of AdER-E2F1 E2F1 infected cells without OHT was set as 100%. The number of viable cells is the mean ± standard deviation of three different wells 6 days after infection. Triplicate experiments were performed for each cell line. (b) Morphologic changes induced by AdER-E2F1. Demonstrated are H1299 cells 48 h following mock infection, treatment with vector control Ad-Luc or AdER-E2F1 in the absence of tamoxifen (left panel) and after 4-OHT induction (right panel) by phase-contrast microscopy. The increasing number of cells that detached from the dish after ER-E2F1 expression in combination with 4-OHT are indicative of apoptosis. (c) 4-OHT-induced transgene cytotoxicity is accompanied by accumulation of cells with a sub-G1 DNA content in FACS analysis consistent with apoptotic cell death. Apoptosis was detected in untreated cells and 24 (I, II) or 72 h (III, IV) following infection in the absence or presence of 4-OHT. The sub-G1 population is indicated as MI.
have demonstrated previously that Ͼ90% transduction efficiency can be achieved in H1299 cells using 10 MOI of adenovirus. 10 7 H1299 cells were mock-infected or infected either with AdER-E2F1 or the control virus AdEGFP at MOI 10 and implanted s.c. into the hind flank of nude mice followed by subsequent induction with tamoxifen. Tamoxifen was administered to mice via s.c. implanted pellets, which release 60 mg over a period of 21 days. At approximately 21 days after tumor cell injection, sizable tumors were apparent in all animals that did not receive 4-OHT, independent of whether cells were Mock-infected, infected with the control virus or AdER-E2F1. Importantly, lack of tumor formation was significant only in mice which received AdER-E2F1 infected tumor cells in combination with 4-OHT, while control vector infected cells showed sustained tumor growth in the presence of 4-OHT. Our results indicate that the tumor suppressor function of adenoviral ER-E2F1 protein can be specifically induced by 4-OHT in vivo. The tumor volumes derived in H1299 cells are shown in Table 1 .
Discussion
The transfer of genes that play a critical role in signaling apoptosis may be valuable in the treatment of cancer. However, related to the toxic, pro-apoptotic activity of transferred gene products, it is for a variety of approaches, ranging from constructing viral vectors in cell culture to human gene therapy important to regulate gene activity tightly. The desired goal of such a regulatory system is to achieve low basal activity, high inducibility, and rapid kinetics of induction and turn off by administration of a non-toxic drug. In the past few years, fusion of proteins to a modified version of the estrogen receptor ligand binding domain (ER) has been proven valuable in rendering transgene activity 4-OHT-dependent by addition of the synthetic ligand 4-OHT. 3, 6, 20 As a significant advantage of this system, compared with other strategies regulating gene expression, 1, 2, 21, 22 regulation takes place on a post-transcriptional level which may allow gene expression under a strong promoter and a more rapid induction of the pre-existing inactive protein by 4-OHT-induced nuclear translocation. We report here the use of the ER-based regulatory system for inducible activation of the apoptotic gene E2F1 in combination with efficient Ad vector-mediated transgene delivery. Infection of human tumor cells with our inducible adenoviral vector revealed fast expression and high levels of chimeric ER-E2F1 protein for at least 1 week. In the presence of 4-OHT, expression was substantially shorter (data not shown) which correlates with the observed E2F1-mediated loss of cell viability. Consistent with previous reports, suggesting that the activity of ERchimeric proteins is regulated by a ligand-induced transport of the protein from the cytosol to the nucleus, 6, 19 adenovirus-expressed ER-E2F1 fusion protein was localized in the nucleus only under activated conditions by administration of 4-OHT.
In our study, induction of E2F-responsive target genes was found to be strictly dependent upon the presence of exogenous 4-OHT, indicating that DNA binding and activation of the E2F1 transcription factor requires 4-OHT. Since there was no basal activity in the absence of tamoxifen, we are able to drive transgene expression by strong promoters which will allow higher E2F1 activity at the time of induction. The excellent dose-response and induction rate characteristics of our 4-OHT inducible system indicated that we can achieve precise control of both the amount and time period for which a potentially toxic gene is induced. The ER-E2F1 transgene activity was induced by 4-OHT in less than 4 h and was completely turned off within 4 h after 4-OHT withdrawal. However, since transgene activity after ligand withdrawal might be determined by protein turnover, the kinetics of shut off may differ depending on the transgene product. We observed different expression levels of the transgene on addition of different amounts of tamoxifen. In correlation with the data in rodent fibroblasts expressing a c-MycER chimeric protein, 3 a maximal response was obtained at a concentration of 100 nm 4-OHT in cell culture: higher concentrations led to no increase in E2F-mediated promoter activity, and up to 10-fold lower concentrations resulted in a medium effect. Since normal cells possess intact cell cycle control mechanisms and disruption of these pathways in tumor cells might confer increased sensitivity to pro-apoptotioc stimuli, 10,23 a 4-OHT-dose dependent variation of the expression levels of toxic transgenes within a therapeutic window may allow a more selective killing of human cancer cells. Together with the fact that intratumoral injection of the Ad vector carrying ER-E2F1 will direct the maximum doses of the treatment to the center of the tumor, this might be efficient to minimize toxicity to normal cells.
Recent studies have demonstrated that overexpression of E2F1 induced generalized apoptosis in quiescent fibroblasts and tumor cell lines independently of the endogenous p53, p16/p21 or RB status. 10, 12, 24 In our experiments, the activation of ER-E2F1 by 4-OHT demonstrated that the expected biological features of adenovirus-expressed E2F1, including E2F-induced cytotoxicity, S-phase entry and apoptosis are tightly dependent upon tamoxifen in both cellular systems. Moreover, our data suggested that the status of p53 or RB does not affect the result of 4-OHT-induced cell death following ER-E2F1 adenoviral infection. Importantly, there was no sign of tamoxifen-induced toxicity, even when the 4-OHTdose was 10-fold higher than that required for a maximum of E2F1 activity. From microscopy, some tox-icity was evident independent of the activated transgene or 4-OHT, in a small fraction of cells infected with the control virus, which is likely attributable to adenoviral early region 4 products shown to be responsible for p53-independent cell death after infection with Ad5-vectors lacking E1 and E3. 25 Finally, the potential of our inducible Ad vector system observed in cell culture was confirmed in an ex vivo animal model. Here, we have shown that tamoxifen maintains its activity in animals without toxic side-effects. Tumor formation was completely inhibited in all sites that received AdER-E2F1-infected tumor cells, indicating a tightly 4-OHT-dependent induction of the toxic transgene under in vivo conditions. In summary, the results presented in this study support the use of an efficient adenoviral gene transfer strategy in conjunction with the ER-based system for fast and tight regulation of pro-apoptotic transcription factors and toxic gene products in a 4-OHT-dose specific manner. Furthermore, the inducible Ad vector system bears the potential for selective induction of controlled apoptosis in tumors compared with normal cells either by modifying the tamoxifen dose or by using tumor specific promoters. This provides us with the ability to translate apoptotic signals efficiently as a major strategy of human cancer gene therapy under safe conditions.
Materials and methods
Cell culture VH6 human primary foreskin fibroblasts (obtained from M Roggendorf, University of Essen), Saos-2 (human osteosarcoma), H1299 (human bronchoalveolar carcinoma), and A549 (human lung carcinoma) cells were maintained in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS). Cell lines were obtained from ATCC (Rockville, MD, USA). All viruses were grown in 293 cells (Ad5 E1-transformed human embryonic kidney cells) maintained in modified Eagle's medium (MEM) F-11 with 10% fetal bovine serum. Media were supplemented with 2 mm l-glutamine, 100 g/ml penicillin, and 100 U/ml streptomycin.
Construction of recombinant plasmids and adenoviral vectors
Plasmids were constructed by standard protocols.
26 Plasmid DNA was prepared by the alkaline lysis method 27 and purified by CsCl-ethidium bromide density gradient centrifugation. The EcoRI cDNA fragment encoding the influenca hemagglutinin (HA)/estrogen receptor ligand binding domain (ER) chimeric protein fused to the Nterminus of the human E2F1 cDNA was obtained from the plasmid pBabeHAERE2F-1. 6 The cDNA for the enhanced green fluorescent protein (EGFP) was obtained from the plasmid pCMVEGFP-Spectrin 28 and for luciferase from the pGL3basic vector (Promega, Mannheim, Germany). The expression cassette for each cDNA was inserted in the E1 region of pMH4 15, 16 under control of the short MCMV IE promoter and terminated by the SV40 large T antigen polyadenylation signal. Adenoviruses expressing foreign genes were obtained by homologous recombination using the pBHG10 system in 293 cells. 17, 18 Ad vectors were constructed, propagated, and
Gene Therapy titered by standard methods. 17, 18, 29 The virus Ad-E2F1 has been described previously. 30 Western blot analysis Cells were infected with AdER-E2F1 at a multiplicity of infection (MOI) of 50 plaque forming units (p.f.u.) per cell. At various times after infection, cell lysates were prepared and protein levels were analyzed essentially as described. 31 The protein content in the lysate was determined by the method of Bradford. 32 Equal amounts of protein were separated by 10% sodium dodecyl sulfatepolyacrylamide gel electrophoresis, transferred to nitrocellulose membranes and probed with mouse anti-human E2F1 monoclonal antibody KH95 (Santa Cruz Biotechnology, Heidelberg, Germany), and developed according to the Amersham enhanced chemiluminescence (ECL) protocol. Relative quantities of E2F1 protein were determined using a densitometer (Molecular Dynamics, Sunnyvale, CA, USA).
Immunofluorescence Cells were grown on coverslips and infected with AdER-E2F1 at 60-80% confluence. Twenty-four hours after infection, activation of the ER-E2F1 fusion protein was induced with 4-OHT for 6 h. To stain for E2F1 expression, cells were subsequently fixed and permeabilized in −20°C cold methanol for 10 min. Coverslips were air dried and stained with the mouse monoclonal anti-HA antibody F-7 (Santa Cruz Biotechnology), followed by a goat antimouse Cy3-conjugated antibody (Jackson ImmunoResearch Laboratories, Dianova, Hamburg, Germany).
Luciferase assay
Saos-2 cells were transfected with 5 g of luciferase reporter contruct and 5 g of ␤-gal plasmid pCMV␤ (Clontech, Heidelberg, Germany) by electroporation. 33 The 6xE2F luciferase construct, pGL3TATA basic 6xE2F, and the human p14ARF exon 1␤ promotor construct, E1␤-Luc, have been described elsewhere. 19, 34 Twelve hours after transfection, cells were seeded on six-well plates and infected with the Ad vector at MOI 10 in 200 l medium for 30 min at 37°C. Cells were subsequently grown in medium to which 4-OHT was added. Cells were collected 48 h after infection in reporter lysis buffer (Promega). Luciferase activities were determined by a premanufactured assay system (Promega). ␤-Galactosidase activities were measured according to standard protocol. 26 To account for differences in transfection efficiencies, luciferase activity was normalized to ␤-galactosidase activity. Error bars represent the standard deviation within a representative experiment. Each experiment has been repeated at least three times.
MTT assay
Cells seeded in 96-wells at 60-80% confluence were infected at MOIs ranging from 10 to 100 depending on the cell line for 30 min at 37°C, to ensure 90-95% infection of all cells. Cell viability was determined in the presence and absence of 4-OHT at a final concentration of 1 m over 6 days after infection. Culture medium was used for mock infection. Triplicate wells of each treatment were assayed for cell viability by the CellTiter96 AQ ueous One Solution Cell Proliferation Assay (Promega).
RT-PCR
Reverse transcription-PCR (RT-PCR) was performed on total RNA prepared by RNeasy Mini Kit (Qiagen, Hilden, Germany) as described previously. 6 PCR amplification was performed using the touchdown technique, decreasing the initial annealing temperature of 60°C 0.5°C per cycle for the first 10 cycles of a total of 26 cycles. Indicated below are the sequences for the upsteam and downstream primers used for each of the tested genes: for the gene encoding cyclin E using 5Ј-CAACATACAGACC CACAGAG-3Ј and 5Ј-CCTTTAGGTCAAGTAGCACC-3Ј; for luciferase using 5Ј-TGGAGAGCAACTGCATAAGG-3Ј and 5Ј-CTGAAATCCCTGGTAATCCG-3Ј.
Flow cytometry
For flow cytometry cells were seeded on 60 mm dishes. At 60-80% confluence cells were infected with adenovirus for 30 min at 37°C. Following infection cells were further incubated in the absence or presence of 1 m 4-OHT. Cells were harvested 24 and 72 h after infection, fixed in 70% ethanol and stained for DNA content with propidium iodide. Flow cytometric analysis was carried out (FACSVantage, Becton Dickinson) and analyzed as described previously using CellQuest software (Becton Dickinson). 35 Animal experiments Six-to 8-week-old nu/nu (nude) mice (Central Animal Facility, University of Essen) were injected subcutaneously (s.c.) into the right flank with 1 × 10 7 H1299 cells infected with AdER-E2F1 or AdEGFP. At the time of cell injection, tamoxifen treatment was started by s.c. implantation of a tamoxifen pellet (IRA, Sarasota, FL, USA), which released 60 mg of ligand over a period of 21-day with a trochar. Mice were monitored for tumor growth at twice weekly intervals and measured in two perpendicular diameters using calipers. Animals were killed when the longest diameter was greater than 15 mm or when any two measurements were greater than 10 mm.
